AbCellera Reports Q3 2026 Results and Positive Phase II Data for ABCL635
AbCellera Biologics Inc. (ABCL) reported third-quarter revenue of $10.6 million, primarily driven by research fees, alongside a net loss of $40.8 million ($0.13 per share). Despite the loss, the company maintains a strong liquidity position with over $890 million in available funds, bolstered by a recent $200 million equity offering and committed government funding. The quarter was highlighted by significant Phase II efficacy data for its lead program, ABCL635, which showed an 83% reduction in vasomotor symptoms (VMS) from baseline. While the company is pivoting toward late-stage clinical development with plans to initiate Phase III trials in 2027, it has strategically discontinued the ABCL575 program for atopic dermatitis following unfavorable class results from competitors like Sanofi and Amgen.
Topics: biotechnology clinical trial data earnings report net loss revenue